Ontology highlight
ABSTRACT:
SUBMITTER: Shaw AT
PROVIDER: S-EPMC4264527 | biostudies-other | 2014 Nov
REPOSITORIES: biostudies-other
Shaw Alice T AT Ou Sai-Hong I SH Bang Yung-Jue YJ Camidge D Ross DR Solomon Benjamin J BJ Salgia Ravi R Riely Gregory J GJ Varella-Garcia Marileila M Shapiro Geoffrey I GI Costa Daniel B DB Doebele Robert C RC Le Long Phi LP Zheng Zongli Z Tan Weiwei W Stephenson Patricia P Shreeve S Martin SM Tye Lesley M LM Christensen James G JG Wilner Keith D KD Clark Jeffrey W JW Iafrate A John AJ
The New England journal of medicine 20140927 21
<h4>Background</h4>Chromosomal rearrangements of the gene encoding ROS1 proto-oncogene receptor tyrosine kinase (ROS1) define a distinct molecular subgroup of non-small-cell lung cancers (NSCLCs) that may be susceptible to therapeutic ROS1 kinase inhibition. Crizotinib is a small-molecule tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), ROS1, and another proto-oncogene receptor tyrosine kinase, MET.<h4>Methods</h4>We enrolled 50 patients with advanced NSCLC who tested positive for ...[more]